What is the price-to-earnings ratio of Nxera Pharma Co?
The price-earnings ratio of Nxera Pharma Co is currently 47.79.
As of Sep 1, 2024, Nxera Pharma Co's P/E ratio was 47.79, a -233.75% change from the -35.73 P/E ratio recorded in the previous year.
The Price to Earnings (P/E) Ratio of Nxera Pharma Co is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.
Assessing Nxera Pharma Co's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.
The P/E ratio of Nxera Pharma Co is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.
Fluctuations in Nxera Pharma Co’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.
The price-earnings ratio of Nxera Pharma Co is currently 47.79.
The price-to-earnings ratio of Nxera Pharma Co has increased by -233.75% fallen (meaning "decreased" or "dropped") compared to last year.
A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.
A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.
Yes, the price-to-earnings ratio of Nxera Pharma Co is high compared to other companies.
An increase in the price-earnings ratio of Nxera Pharma Co would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.
A decrease in the price-earnings ratio of Nxera Pharma Co would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.
Some factors that influence the price-earnings ratio of Nxera Pharma Co are the company's growth, financial position, industry development, and the overall economic situation.
Over the past 12 months, Nxera Pharma Co paid a dividend of 2.5 JPY . This corresponds to a dividend yield of about 0.18 %. For the coming 12 months, Nxera Pharma Co is expected to pay a dividend of 0 JPY.
The current dividend yield of Nxera Pharma Co is 0.18 %.
Nxera Pharma Co pays a quarterly dividend. This is distributed in the months of .
Nxera Pharma Co paid dividends every year for the past 0 years.
For the upcoming 12 months, dividends amounting to 0 JPY are expected. This corresponds to a dividend yield of 0 %.
Nxera Pharma Co is assigned to the 'Health' sector.
To receive the latest dividend of Nxera Pharma Co from 6/24/2015 amounting to 10 JPY, you needed to have the stock in your portfolio before the ex-date on 3/27/2015.
The last dividend was paid out on 6/24/2015.
In the year 2023, Nxera Pharma Co distributed 0 JPY as dividends.
The dividends of Nxera Pharma Co are distributed in JPY.
Our stock analysis for Nxera Pharma Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Nxera Pharma Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.